NKTR Nektar Therapeutics - Common Stock
$75,92
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 14, 2026
52 Haftlık Aralık
$25–$109
60% of range
Analist Derecelendirmesi
BUY
17 analysts
Fiyat Hedefi
$153
+102% upside
P/E (TTM)
-11.3
ROE
-500.1%
Net Kâr Marjı
-297.1%
Nektar Therapeutics - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Devamını oku
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
NKTR Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$75.92
Piyasa Değeri
$2.24B
P/E (TTM)
-11.3
EPS (TTM)
$-9.73
Gelir (TTM)
$55M
Temettü Verimi
—
ROE
-500.1%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$25 – $109
NKTR Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$55M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-9.73
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
$-209M
2016-12-31
→
2025-12-31
Marjlar
-297.1%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
NKTR
Akran Ortalaması
P/E (TTM)
-11.3
29.4
P/S (TTM) (F/S (TTM))
40.5
4.9
P/B (F/D)
24.9
6.5
Price / FCF (Fiyat / Serbest Nakit Akışı)
-10.7
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
NKTR
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
-253.7%
—
Net Profit Margin (Net Kâr Marjı)
-297.1%
-9.0%
ROA
-56.2%
-8.2%
ROE
-500.1%
-19.4%
ROIC
-155.8%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
NKTR
Akran Ortalaması
Current Ratio (Cari Oran)
5.0
3.6
Quick Ratio (Cari Oran)
0.3
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
NKTR
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
-43.9%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
-15.7%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
-18.4%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
NKTR
Akran Ortalaması
NKTR Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
17 analist
- Güçlü Al 7 41,2%
- Al 8 47,1%
- Tut 2 11,8%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
9 analist · 2026-08-16
Medyan
$151.00
← Tüm hedeflerin altında
$75.92
Düşük
$80.00
Yüksek
$192.00
Medyan hedef
$151.00
+98,9%
Ortalama hedef
$153.22
+101,8%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.21%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $-1.23 | $-2.02 | 0.79% |
| 31 Mart 2026 | $-1.82 | $-1.63 | -0.19% |
| 31 Aralık 2025 | $-1.78 | $-2.52 | 0.74% |
| 30 Eylül 2025 | $-1.87 | $-2.74 | 0.87% |
| 30 Haziran 2025 | $-2.95 | $-3.10 | 0.15% |
| 31 Mart 2025 | $-3.60 | $-2.51 | -1.1% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | — |
| ALMS | — | -3.4 | — | -1011.8% | -61.9% | — |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | — |
| SUPN | $2.86B | -73.1 | 8.6% | -5.4% | -3.6% | — |
| ATAI | $223M | -1.4 | -1.9% | -48464.0% | -83.1% | — |
| TRVI | $1.61B | -39.1 | — | — | -22.4% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| AMLX | $1.33B | -7.9 | -77.1% | — | -61.2% | — |
| PBH | $3.33B | 15.2 | -4.3% | 17.5% | 10.2% | 54.7% |
| RAPP | $1.45B | -10.6 | — | — | -29.8% | — |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
Bilanço 24
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
Nakit Akışı 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
Likidite ve Solventlik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
Büyüme Oranları 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 10
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
Gelir Tablosu 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
Bilanço 23
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
Nakit Akışı 12
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
Kârlılık 7
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
Verimlilik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
Değerleme (TTM) 10
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44M | $44M | · | $58M | $69M | $80M | · | $93M | $90M | $88M | · | $90M | $87M | $92M | · | $95M | |
| Net Income TTM | $-163M | $-173M | · | $-165M | $-182M | $-177M | · | $-172M | $-186M | $-271M | · | $-293M | $-406M | $-446M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -8.9 | -7.0 | · | -7.4 | -2.7 | -1.5 | · | -2.8 | -4.2 | -9.8 | · | -5.8 | -4.0 | -4.4 | · | -0.1 | |
| P/S | 32.4 | 33.1 | · | 19.4 | 4.6 | 23.8 | · | 38.5 | 38.1 | 29.1 | · | 19.1 | 18.9 | 21.7 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| P / FCF | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.3 | · | · | · | -38.0 | · | · | |
| Earnings Yield | -11.3% | -14.3% | · | -13.6% | -37.2% | -67.2% | · | -35.1% | -24.0% | -10.2% | · | -17.2% | -24.8% | -22.7% | · | -1649.3% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $55M | $98M | $90M | $92M | $102M |
| Faaliyet Kâr Marjı % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Net Gelir | $-164M | $-119M | $-276M | $-368M | $-524M |
| Seyreltilmiş Hisse Başı Kâr | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| Cari Oran | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-209M | $-177M | $-193M | $-310M | $-428M |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 269 dosya · $2.1B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 88 (+20 önceki Ç'ye göre) | 41 (+9 önceki Ç'ye göre) | 91 (+21 önceki Ç'ye göre) | 48 (-8 önceki Ç'ye göre) | +8.5M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| Two Seas Capital LP | $215.868.856 | 3.092.234 | 10,35% | Hisse senetleri |
| FMR LLC | $192.088.149 | 2.751.585 | 9,21% | Hisse senetleri |
| BVF INC/IL | $166.920.946 | 2.391.075 | 8,00% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $104.495.029 | 1.496.849 | 5,01% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $83.911.899 | 1.202.004 | 4,02% | Hisse senetleri |
| Vestal Point Capital, LP | $69.810.000 | 1.000.000 | 3,35% | Hisse senetleri |
| STATE STREET CORP | $63.504.691 | 909.679 | 3,04% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57.502.497 | 823.700 | 2,76% | Alım opsiyonu |
| Prosight Management, LP | $56.546.100 | 810.000 | 2,71% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $52.759.799 | 755.586 | 2,53% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $50.542.440 | 724.000 | 2,42% | Hisse senetleri |
| GILDER GAGNON HOWE & CO LLC | $41.946.944 | 600.873 | 2,01% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $33.377.557 | 478.120 | 1,60% | Hisse senetleri |
| BRAIDWELL LP | $33.063.203 | 473.617 | 1,59% | Hisse senetleri |
| Sofinnova Investments, Inc. | $32.933.775 | 471.763 | 1,58% | Hisse senetleri |
| Woodline Partners LP | $32.871.784 | 470.875 | 1,58% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $32.485.804 | 465.346 | 1,56% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27.540.045 | 394.500 | 1,32% | Satım opsiyonu |
| EMERALD ADVISERS, LLC | $27.236.930 | 390.158 | 1,31% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24.331.577 | 348.540 | 1,17% | Hisse senetleri |
| DAFNA Capital Management LLC | $22.226.108 | 318.380 | 1,07% | Hisse senetleri |
| Deep Track Capital, LP | $20.943.000 | 300.000 | 1,00% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19.893.826 | 284.971 | 0,95% | Hisse senetleri |
| 22NW, LP | $19.624.638 | 281.115 | 0,94% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.475.384 | 278.977 | 0,93% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $19.047.658 | 272.850 | 0,91% | Hisse senetleri |
| Nearwater Capital Markets, Ltd | $18.255.315 | 261.500 | 0,88% | Hisse senetleri |
| BARCLAYS PLC | $17.968.815 | 257.396 | 0,86% | Hisse senetleri |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17.842.528 | 255.587 | 0,86% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $17.046.485 | 244.184 | 0,82% | Hisse senetleri |
| Creek Drive Management Group LLC | $16.963.830 | 243.000 | 0,81% | Hisse senetleri |
| SEVEN GRAND MANAGERS, LLC | $16.754.400 | 240.000 | 0,80% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $16.724.731 | 239.575 | 0,80% | Hisse senetleri |
| NORGES BANK | $15.030.093 | 215.300 | 0,72% | Hisse senetleri |
| Bronte Capital Management Pty Ltd. | $13.852.678 | 198.434 | 0,66% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $13.039.744 | 308.414 | 0,63% | Hisse senetleri |
| CITADEL ADVISORS LLC | $12.251.655 | 175.500 | 0,59% | Satım opsiyonu |
| GREAT POINT PARTNERS LLC | $12.216.750 | 175.000 | 0,59% | Hisse senetleri |
| Caption Management, LLC | $11.944.491 | 171.100 | 0,57% | Alım opsiyonu |
| MILLENNIUM MANAGEMENT LLC | $11.867.700 | 170.000 | 0,57% | Alım opsiyonu |
| CITADEL ADVISORS LLC | $11.434.878 | 163.800 | 0,55% | Alım opsiyonu |
| AMERIPRISE FINANCIAL INC | $11.050.085 | 158.288 | 0,53% | Hisse senetleri |
| Quinn Opportunity Partners LLC | $10.686.236 | 153.076 | 0,51% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $10.011.801 | 143.415 | 0,48% | Hisse senetleri |
| Rhenman & Partners Asset Management AB | $9.860.662 | 141.250 | 0,47% | Hisse senetleri |
| Qube Research & Technologies Ltd | $9.111.671 | 130.521 | 0,44% | Hisse senetleri |
| LMR Partners LLP | $9.075.300 | 130.000 | 0,44% | Satım opsiyonu |
| Soleus Capital Management, L.P. | $8.960.951 | 128.362 | 0,43% | Hisse senetleri |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $8.570.364 | 122.767 | 0,41% | Hisse senetleri |
| Stonepine Capital Management, LLC | $8.422.856 | 120.654 | 0,40% | Hisse senetleri |
| SummitTX Capital, L.P. | $7.883.923 | 112.934 | 0,38% | Hisse senetleri |
| APEIRON CAPITAL Ltd | $7.429.948 | 106.431 | 0,36% | Hisse senetleri |
| CITIGROUP INC | $7.034.824 | 100.771 | 0,34% | Hisse senetleri |
| ING GROEP NV | $6.981.000 | 100.000 | 0,33% | Hisse senetleri |
| LMR Partners LLP | $6.981.000 | 100.000 | 0,33% | Hisse senetleri |
| Susquehanna Portfolio Strategies, LLC | $6.685.704 | 95.770 | 0,32% | Hisse senetleri |
| Militia Capital Management LLC | $6.282.900 | 90.000 | 0,30% | Hisse senetleri |
| ACT CAPITAL MANAGEMENT, LLC | $6.234.033 | 89.300 | 0,30% | Hisse senetleri |
| Tetragon Partners GP Ltd | $6.073.191 | 86.996 | 0,29% | Hisse senetleri |
| READYSTATE ASSET MANAGEMENT LP | $5.941.529 | 85.110 | 0,28% | Hisse senetleri |
| Birchview Capital, LP | $5.654.610 | 81.000 | 0,27% | Hisse senetleri |
| BlackRock, Inc. | $5.444.412 | 77.989 | 0,26% | Hisse senetleri |
| GROUP ONE TRADING LLC | $4.912.600 | 70.371 | 0,24% | Hisse senetleri |
| ALGERT GLOBAL LLC | $4.686.345 | 67.130 | 0,22% | Hisse senetleri |
| Moody Aldrich Partners LLC | $4.477.264 | 64.135 | 0,21% | Hisse senetleri |
| WOLVERINE TRADING, LLC | $4.330.620 | 73.500 | 0,21% | Satım opsiyonu |
| Swiss National Bank | $4.300.296 | 61.600 | 0,21% | Hisse senetleri |
| F/m Investments LLC | $4.229.439 | 60.585 | 0,20% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $4.227.764 | 60.561 | 0,20% | Hisse senetleri |
| ExodusPoint Capital Management, LP | $4.084.374 | 58.507 | 0,20% | Hisse senetleri |
| Trexquant Investment LP | $3.956.831 | 56.680 | 0,19% | Hisse senetleri |
| K2 PRINCIPAL FUND, L.P. | $3.522.962 | 50.465 | 0,17% | Hisse senetleri |
| WOLVERINE TRADING, LLC | $3.403.101 | 57.758 | 0,16% | Hisse senetleri |
| RHUMBLINE ADVISERS | $3.008.381 | 43.094 | 0,14% | Hisse senetleri |
| MORGAN STANLEY | $2.943.050 | 42.158 | 0,14% | Hisse senetleri |
| Voleon Capital Management LP | $2.850.901 | 40.838 | 0,14% | Hisse senetleri |
| Anson Funds Management LP | $2.829.748 | 40.535 | 0,14% | Hisse senetleri |
| Atom Investors LP | $2.828.631 | 40.519 | 0,14% | Hisse senetleri |
| WOLVERINE TRADING, LLC | $2.792.808 | 47.400 | 0,13% | Alım opsiyonu |
| Burkehill Global Management, LP | $2.792.400 | 40.000 | 0,13% | Hisse senetleri |
| NOMURA HOLDINGS INC | $2.792.400 | 40.000 | 0,13% | Satım opsiyonu |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $2.708.768 | 38.802 | 0,13% | Hisse senetleri |
| NOMURA HOLDINGS INC | $2.698.645 | 38.657 | 0,13% | Hisse senetleri |
| Jefferies Financial Group Inc. | $2.664.299 | 38.165 | 0,13% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $2.590.200 | 36.000 | 0,12% | Hisse senetleri |
| Connor, Clark & Lunn Investment Management Ltd. | $2.575.780 | 36.897 | 0,12% | Hisse senetleri |
| ALPS ADVISORS INC | $2.386.664 | 34.188 | 0,11% | Hisse senetleri |
| FRED ALGER MANAGEMENT, LLC | $2.350.712 | 33.673 | 0,11% | Hisse senetleri |
| TUDOR INVESTMENT CORP ET AL | $2.345.616 | 33.600 | 0,11% | Alım opsiyonu |
| Bank of New York Mellon Corp | $2.306.522 | 33.040 | 0,11% | Hisse senetleri |
| Ghisallo Capital Management LLC | $2.233.920 | 32.000 | 0,11% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2.063.670 | 28.682 | 0,10% | Hisse senetleri |
| Blackstone Inc. | $2.002.011 | 28.678 | 0,10% | Hisse senetleri |
| KVP Capital Advisors, LP | $1.877.889 | 26.900 | 0,09% | Hisse senetleri |
| Ishara Investments LP | $1.860.437 | 26.650 | 0,09% | Hisse senetleri |
| Erste Asset Management GmbH | $1.830.920 | 28.000 | 0,09% | Hisse senetleri |
| Caption Management, LLC | $1.822.041 | 26.100 | 0,09% | Satım opsiyonu |
| WINTON GROUP Ltd | $1.808.079 | 25.900 | 0,09% | Hisse senetleri |
| K2 PRINCIPAL FUND, L.P. | $1.745.250 | 25.000 | 0,08% | Alım opsiyonu |
| Empowered Funds, LLC | $1.636.416 | 23.441 | 0,08% | Hisse senetleri |
Şirket yöneticileri 40 içeriden öğrenenler · 20 yöneticiler · 18 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 24 Temmuz 2026 A | 55.045 | 0 | 20 | $-2.224.055 |
| Jillian B. Thomsen | Chief Financial Officer | 16 Şubat 2023 S | 313.497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16 Mayıs 2022 S | 312.905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23 Ağustos 2007 A | — | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14 Mayıs 2007 A | 6.000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 04 Mart 2004 S | 743.904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16 Ağustos 2019 S | 162.759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 01 Şubat 2010 A | — | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 24 Temmuz 2026 A | 9.756 | 0 | 12 | $-1.052.364 |
| Mark Andrew Wilson | Chief Legal Officer | 21 Kasım 2025 A | 21.585 | 0 | 2 | $-52.171 |
| John Northcott | SVP & Chief Commercial Officer | 16 Mayıs 2022 S | 223.210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 05 Eylül 2019 P | 107.668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16 Mayıs 2019 S | 94.694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15 Kasım 2017 A | 56.553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 05 Şubat 2014 A | — | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 06 Şubat 2013 A | 9.753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23 Şubat 2009 A | — | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14 Kasım 2008 M | 313.880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25 Şubat 2008 A | 1.400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14 Mayıs 2007 D | 6.600 | 0 | 0 | $0 |
| Diana Brainard | Yönetim kurulu üyesi | 30 Eylül 2025 A | 28.560 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | Yönetim kurulu üyesi | 30 Eylül 2025 A | 34.153 | 0 | 0 | $0 |
| Robert Chess | Yönetim kurulu üyesi | 30 Eylül 2025 A | 255.273 | 0 | 0 | $0 |
| Scott R Greer | Yönetim kurulu üyesi | 30 Eylül 2025 A | 303.574 | 0 | 0 | $0 |
| Roy A Whitfield | Yönetim kurulu üyesi | 30 Eylül 2025 A | 216.250 | 0 | 0 | $0 |
| Myriam Curet | Yönetim kurulu üyesi | 19 Eylül 2023 A | 27.418 | 0 | 0 | $0 |
| Karin Eastham | Yönetim kurulu üyesi | 16 Eylül 2022 A | 23.233 | 0 | 0 | $0 |
| Lutz Lingnau | Yönetim kurulu üyesi | 22 Eylül 2020 A | 35.800 | 0 | 0 | $0 |
| Christopher A Kuebler | Yönetim kurulu üyesi | 27 Eylül 2018 A | 45.250 | 0 | 0 | $0 |
| Dennis L Winger | Yönetim kurulu üyesi | 21 Ağustos 2018 M | 42.750 | 0 | 0 | $0 |
| Joseph J Krivulka | Yönetim kurulu üyesi | 19 Eylül 2017 A | 82.000 | 0 | 0 | $0 |
| Susan Wang | Yönetim kurulu üyesi | 20 Kasım 2015 M | 20.000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | Yönetim kurulu üyesi | 15 Eylül 2009 A | 10.000 | 0 | 0 | $0 |
| Hoyoung Huh | Yönetim kurulu üyesi | 02 Aralık 2008 A | — | 0 | 0 | $0 |
| Irwin Lerner | Yönetim kurulu üyesi | 02 Aralık 2008 A | 10.000 | 0 | 0 | $0 |
| James B Glavin | Yönetim kurulu üyesi | 04 Eylül 2003 A | — | 0 | 0 | $0 |
| Masuoka K. Lorianne | — | 08 Şubat 2011 A | — | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23 Mart 2006 S | 87.991 | 0 | 0 | $0 |
| Ajay Bansal | — | 10 Mart 2006 S | 5.166 | 0 | 0 | $0 |
| Melvin Perelman | — | 02 Eylül 2004 A | — | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22 Ağustos 2005 | — | İlk başvuru | M&A / satış | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 28 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,14% | 50.876 NS | 31 Mayıs 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 3,11% | 10.455 NS | 30 Nisan 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,55% | 2.353 NS | 30 Nisan 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,15% | 5.045 NS | 30 Nisan 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,58% | 1.726 SH | 08 Ağustos 2026 | Günlük |
| IHE · iShares Trust | 0,55% | 120.730 SH | 08 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 59.612 SH | 08 Ağustos 2026 | Günlük |
| IWO · iShares Trust | 0,14% | 278.376 SH | 08 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33.135 SH | 08 Ağustos 2026 | Günlük |
| TMFX · RBB Fund, Inc. | 0,09% | 455 NS | 31 Mayıs 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 877.973 SH | 08 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198.365 SH | 08 Ağustos 2026 | Günlük |
| ISCV · iShares Trust | 0,07% | 6.414 SH | 08 Ağustos 2026 | Günlük |
| SCHA · SCHWAB STRATEGIC TRUST | 0,04% | 151.830 NS | 31 Mayıs 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 11.131 NS | 30 Nisan 2026 | N-PORT |
| ISCB · iShares Trust | 0,03% | 1.294 SH | 08 Ağustos 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387.471 SH | 08 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,03% | 92.340 SH | 08 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,02% | 1.887 SH | 08 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3.096 SH | 08 Ağustos 2026 | Günlük |
| IWN · iShares Trust | 0,02% | 32.466 SH | 08 Ağustos 2026 | Günlük |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 6.903 NS | 31 Mayıs 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 48.124 SH | 08 Ağustos 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 9.139 SH | 08 Ağustos 2026 | Günlük |
| TILT · FlexShares Trust | 0,00% | 770 NS | 30 Nisan 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 18.540 NS | 31 Mayıs 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.075.430 SH | 08 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.837 SH | 08 Ağustos 2026 | Günlük |